Animal models of chronic graft versus host disease

Chronic Graft Versus Host Disease: Interdisciplinary Management

Volumn , Issue , 2009, Pages 31-45

  Chu, Yu Waye ^a   Gress, Ronald ^a   Shlomchik, Warren D ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84862855645     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511576751.005     Document Type: Chapter

References (158)

1. Baird K, Pavletic SZ. Chronic graft versus host disease. Curr Opin Hematol. 2006;13:426–435.
2. Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft- versus- host disease: association with treatment-related mortality and relapse. Blood. 2002;100:406–414.
3. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945–956.
4. Couriel D, Carpenter PA, Cutler C, et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2006;12:375–396.
5. Martin PJ, Weisdorf D, Przepiorka D, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant. 2006;12:491–505
6. Pavletic SZ, Martin P, Lee SJ et al Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant. 2006;12:252–266.
7. Schultz KR, Miklos DB, Fowler D, et al. Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. Biol Blood Marrow Transplant. 2006;12:126–137.
8. Shulman HM, Kleiner D, Lee SJ, et al. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant. 2006;12:31–47.
9. Lee SJ. New approaches for preventing and treating chronic graft-versus-host disease. Blood. 2005;105:4200–4206.
10. Collins RH, Jr., Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433–444.
11. Parkman R. Is chronic graft versus host disease an autoimmune disease? Curr Opin Immunol. 1993;5:800–803.
12. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007;7:340–352.
13. Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant. 1999;5:347–356.
14. Van der Veen F, Rolink AG, Gleichmann E. Diseases caused by reactions of T lymphocytes to incompatible structures of the major histocompatibility complex. IV. Autoantibodies to nuclear antigens. Clin Exp Immunol. 1981;46:589–596.
15. van der Veen FM, Rolink AG, Gleichmann E. Autoimmune disease strongly resembling systemic lupus erythematosus (SLE) in F1 mice undergoing graft-versus-host reaction (GVHR). Adv Exp Med Biol. 1982;149:669–677.
16. van Rappard-van der Veen FM, Rolink AG, Gleichmann E. Diseases caused by reactions of T lymphocytes towards incompatible structures of the major histocompatibility complex. VI. Autoantibodies characteristic of systemic lupus erythematosus induced by abnormal T-B cell cooperation across I-E. J Exp Med. 1982;155:1555–1560.
17. Gleichmann H, Gleichmann E, Andre-Schwartz J, Schwartz RS. Chronic allogeneic disease. 3. Genetic requirements for the induction of glomerulonephritis. J Exp Med. 1972;135:516–532.
18. Lewis RM, Armstrong MY, Andre-Schwartz J, Muftuoglu A, Beldotti L, Schwartz RS. Chronic allogeneic disease. I. Development of glomerulonephritis. J Exp Med. 1968;128:653–679.
19. Patriarca F, Skert C, Sperotto A, et al. The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. Exp Hematol. 2006;34:389–396.
20. Rouquette-Gally AM, Boyeldieu D, Gluckman E, Abuaf N, Combrisson A. Autoimmunity in 28 patients after allogeneic bone marrow transplantation: comparison with Sjogren syndrome and scleroderma. Br J Haematol. 1987;66:45–47.
21. Rouquette-Gally AM, Boyeldieu D, Prost AC, Gluckman E. Autoimmunity after allogeneic bone marrow transplantation. A study of 53 long-term-surviving patients. Transplantation.1988;46:238–240.
22. Wechalekar A, Cranfield T, Sinclair D, Ganzckowski M. Occurrence of autoantibodies in chronic graft vs. host disease after allogeneic stem cell transplantation. Clin Lab Haematol. 2005;27:247–249.
23. Zorn E, Miklos DB, Floyd BH, et al. Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. J Exp Med. 2004;199:1133–1142.
24. Miklos DB, Kim HT, Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005; 105:2973–2978.
25. Miklos DB, Kim HT, Zorn E, et al. Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood. 2004;103:353–359.
26. Chan OT, Shlomchik MJ., Cutting edge: B cells promote CD8+ T cell activation in MRL-Fas(lpr) mice independently of MHC class I antigen presentation. J Immunol. 2000;164:1658–1662.
27. Shlomchik MJ, Craft JE, Mamula MJ. From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol. 2001;1:147–153.
28. Zhong G, Reis e Sousa C, Germain RN. Antigen-unspecific B cells and lymphoid dendritic cells both show extensive surface expression of processed antigen-major histocompatibility complex class II complexes after soluble protein exposure in vivo or in vitro. J Exp Med. 1997;186:673–682.
29. van der Veen JP, Rolink AG, Gleichmann E. Diseases caused by reactions of T lymphocytes to incompatible structures of the major histocompatibility complex. III. Autoantibodies to thymocytes. J Immunol. 1981;127:1281–1286.
30. Van Elven EH, Rolink AG, Veen FV, Gleichmann E. Capacity of genetically different T lymphocytes to induce lethal graftversus- host disease correlates with their capacity to generate suppression but not with their capacity to generate anti-F1 killer cells. A non-H-2 locus determines the inability to induce lethal graft-versus-host disease. J Exp Med. 1981;153:1474–1488.
31. van Elven EH, van der Veen FM, Rolink AG, Issa P, Duin TM, Gleichmann E. Diseases caused by reactions of T lymphocytes to incompatible structures of the major histocompatibility complex. V. High titers of IgG autoantibodies to doublestranded DNA. J Immunol. 1981;127:2435–2438.
32. Rolink AG, Radaszkiewicz T, Pals ST, van der Meer WG, Gleichmann E. Allosuppressor and allohelper T cells in acute and chronic graft-vs-host disease. I. Alloreactive suppressor cells rather than killer T cells appear to be the decisive effector cells in lethal graft-vs.-host disease. J Exp Med. 1982;155:1501–1522.
33. Rolink AG, Gleichmann E. Allosuppressor- and allohelper-T cells in acute and chronic graft-vs.-host (GVH) disease. III. Different Lyt subsets of donor T cells induce different pathological syndromes. J Exp Med. 1983;158:546–558.
34. Rolink AG, Gleichmann H, Gleichmann E. Diseases caused by reactions of T lymphocytes to incompatible structures of the major histocompatibility complex. VII. Immune-complex glomerulonephritis. J Immunol. 1983;130:209–215.
35. Via CS, Sharrow SO, Shearer GM. Role of cytotoxic T lymphocytes in the prevention of lupus-like disease occurring in a murine model of graft-vs-host disease. J Immunol. 1987;139:1840–1849.
36. Via CS. Kinetics of T cell activation in acute and chronic forms of murine graft-versus-host disease. J Immunol. 1991; 146:2603–2609.
37. Via CS, Rus V, Gately MK, Finkelman FD. IL-12 stimulates the development of acute graft-versus-host disease in mice that normally would develop chronic, autoimmune graft-versushost disease. J Immunol. 1994;153:4040–4047.
38. Bruijn JA, Hogendoorn PC, Corver WE, van den Broek LJ, Hoedemaeker PJ, Fleuren GJ. Pathogenesis of experimental lupus nephritis: a role for anti-basement membrane and anti-tubular brush border antibodies in murine chronic graft-versus-host disease. Clinical & Experimental Immunology. 1990;79:115–122.
39. Bruijn JA, Van Elven EH, Corver WE, Oudshoorn-Snoek M, leuren GJ. Genetics of experimental lupus nephritis: non- H-2 factors determine susceptibility for renal involvement in murine chronic graft-versus-host disease. Clin Exp Immunol. 1989;76:284–289.
40. Rolink AG, Pals ST, Gleichmann E. Allosuppressor and allohelper T cells in acute and chronic graft-vs.-host disease. II. F1 recipients carrying mutations at H-2K and/or I-A. J Exp Med. 1983;157:755–771.
41. Morris SC, Cheek RL, Cohen PL, Eisenberg RA. Autoantibodies in chronic graft versus host result from cognate T-B interactions. J Exp Med. 1990;171:503–517.
42. Morris SC, Cheek RL, Cohen PL, Eisenberg RA. Allotypespecific immunoregulation of autoantibody production by host B cells in chronic graft-versus host disease. J Immunol. 1990;144:916–922.
43. Morris SC, Cohen PL, Eisenberg RA. Experimental induction of systemic lupus erythematosus by recognition of foreign Ia. Clin Immunol Immunopathol. 1990;57:263–273.
44. Shankar G, Bryson JS, Jennings CD, Morris PE, Cohen DA. Idiopathic pneumonia syndrome in mice after allogeneic bone marrow transplantation. Am J Respir Cell Mol Biol. 1998;18:235–242.
45. Shankar G, Scott Bryson J, Darrell Jennings C, Kaplan AM, Cohen DA. Idiopathic pneumonia syndrome after allogeneic bone marrow transplantation in mice. Role of pretransplant radiation conditioning. Am J Respir Cell Mol Biol. 1999;20:1116–1124.
46. Via CS, Sharrow SO, Shearer GM. Role of cytotoxic T lymphocytes in the prevention of lupus-like disease occurring in a murine model of graft-vs-host disease. J Immunol. 1987;139: 1840–1849.
47. Shustov A, Luzina I, Nguyen P, et al. Role of perforin in controlling B-cell hyperactivity and humoral autoimmunity. J Clin Invest. 2000;106:R39–47.
48. De Wit D, Van Mechelen M, Zanin C, et al. Preferential activation of Th2 cells in chronic graft-versus-host reaction. J Immunol. 1993;150:361–366.
49. Garlisi CG, Pennline KJ, Smith SR, Siegel MI, Umland SP. Cytokine gene expression in mice undergoing chronic graftversus- host disease. Mol Immunol. 1993;30:669–677.
50. Durie FH, Aruffo A, Ledbetter J, et al. Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease. J Clin Invest. 1994;94:1333–1338.
51. Via CS, Rus V, Nguyen P, Linsley P, Gause WC. Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD. J Immunol. 1996;157:4258–4267.
52. Via CS, Rus V, Gately MK, Finkelman FD. IL-12 stimulates the development of acute graft-versus-host disease in mice that normally would develop chronic, autoimmune graft-versushost disease. J Immunol. 1994;153:4040–4047.
53. Okubo T, Hagiwara E, Ohno S, et al. Administration of an IL-12-encoding DNA plasmid prevents the development of chronic graft-versus-host disease (GVHD). J Immunol. 1999;162:4013–4017.
54. Ratanatharathorn V, Ayash L, Reynolds C, et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant. 2003;9:505–511.
55. Vinuesa CG, Tangye SG, Moser B, Mackay CR. Follicular B helper T cells in antibody responses and autoimmunity. Nat Rev Immunol. 2005;5:853–865.
56. Murphy WJ. Revisiting graft-versus-host disease models of autoimmunity: new insights in immune regulatory processes. J Clin Invest. 2000;106:745–747.
57. Subramaniam DS, Fowler DH, Pavletic SZ. Chronic graft-versus- host disease in the era of reduced-intensity conditioning. Leukemia. 2007;21:853–859.
58. Sykes M, Preffer F, McAfee S, et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after nonmyeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet. 1999;353:1755–1759.
59. Hamilton BL, Bevan MJ, Parkman R. Anti-recipient cytotoxic T lymphocyte precursors are present in the spleens of mice with acute graft versus host disease due to minor histocompatibility antigens. J Immunol. 1981;126:621–625.
60. Jaffee BD, Claman HN. Chronic graft-versus-host disease (GVHD) as a model for scleroderma. I. Description of model systems. Cell Immunol. 1983;77:1–12.
61. Giorno R, Choi KL, Katz HR, Claman HN. Monoclonal antibody analysis of skin in chronic murine graft vs host disease produced across minor histocompatibility barriers. Cell Immunol. 1987;106:76–87.
62. Howell CD, Yoder T, Claman HN, Vierling JM. Hepatic homing of mononuclear inflammatory cells isolated during murine chronic graft-vs-host disease. J Immunol. 1989;143:476–483.
63. Vierling JM, Ruderman WB, Jaffee BD, Fennell R, Jr., Claman HN. Hepatic lesions in murine chronic graft-versus-host disease to minor histocompatibility antigens. A reproducible model of nonsuppurative destructive cholangitis. Transplantation. 1989;48:717–718.
64. Nagler RM, Laufer D, Nagler A. Parotid gland dysfunction in an animal model of chronic graft-vs-host disease. Arch Otolaryngol Head Neck Surg. 1996;122:1057–1060.
65. Nagler RM, Laufer D, Nagler A. Parotid gland dysfunction in a murine model of acute graft versus host disease [aGVHD]. Head Neck. 1998;20:58–62.
66. Korngold R, Sprent J. Variable capacity of L3T4+ T cells to cause lethal graft-versus-host disease across minor histocompatibility barriers in mice. J Exp Med. 1987;165:1552–1564.
67. Hamilton BL. L3T4-positive T cells participate in the induction of graft-vs-host disease in response to minor histocompatibility antigens. J Immunol. 1987;139:2511–2515.
68. Kaplan DH, Anderson BE, McNiff JM, Jain D, Shlomchik MJ, Shlomchik WD. Target Antigens Determine Graft-versus-Host Disease Phenotype. J Immunol. 2004;173:5467–5475.
69. Anderson BE, McNiff J, Yan J, et al. Memory CD4+ T cells do not induce graft-versus-host disease. J Clin Invest. 2003;112:101–108.
70. Anderson BE, McNiff J, Matte C, Athanasiadis I, Shlomchik WD, Shlomchik MJ. Recipient CD4+ T Cells That Survive Irradiation Regulate Chronic Graft-vs.-Host Disease. Blood. 2004;104(5):1565–1573.
71. Anderson BE, McNiff JM, Jain D, Blazar BR, Shlomchik WD, Shlomchik MJ. Distinct roles for donor- and host-derived antigen- presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood. 2005;105:2227–2234.
72. Lundqvist A, McCoy JP, Samsel L, Childs R. Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors. Blood. 2007;109:3603–3606.
73. DiSanto JP, Bonnefoy JY, Gauchat JF, Fischer A, de Saint Basile G. CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM [see comments]. Nature. 1993;361: 541–543.
74. Askew D, Zhou L, Wu C, Chen G, Gilliam AC. Absence of cutaneous TNFalpha-producing CD4+ T cells and TNFalpha may allow for fibrosis rather than epithelial cytotoxicity in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol. 2007;127:1905–1914.
75. Zhou L, Askew D, Wu C, Gilliam AC. Cutaneous gene expression by DNA microarray in murine sclerodermatous graftversus- host disease, a model for human scleroderma. J Invest Dermatol. 2007;127:281–292.
76. Zhang Y, McCormick LL, Gilliam AC. Latency-associated peptide prevents skin fibrosis in murine sclerodermatous graftversus- host disease, a model for human scleroderma. J Invest Dermatol. 2003;121:713–719.
77. McCormick LL, Zhang Y, Tootell E, Gilliam AC. Anti-TGFbeta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol. 1999;163:5693–5699.
78. Zhang Y, McCormick LL, Desai SR, Wu C, Gilliam AC. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol. 2002;168:3088–3098.
79. Aoki CA, Borchers AT, Li M, et al. Transforming growth factor beta (TGF-beta) and autoimmunity. Autoimmun Rev. 2005;4:450–459.
80. Banovic T, MacDonald KP, Morris ES, et al. TGF-beta in allogeneic stem cell transplantation: friend or foe? Blood. 2005;106:2206–2214.
81. Granot I, Bartov I, Plavnik I, Wax E, Hurwitz S, Pines M. Increased skin tearing in broilers and reduced collagen synthesis in skin in vivo and in vitro in response to the coccidiostat halofuginone. Poult Sci. 1991;70:1559–1563.
82. Granot I, Halevy O, Hurwitz S, Pines M. Halofuginone: an inhibitor of collagen type I synthesis. Biochim Biophys Acta. 1993;1156:107–112.
83. McGaha TL, Phelps RG, Spiera H, Bona C. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. J Invest Dermatol. 2002;118: 461–470.
84. Leiba M, Cahalon L, Shimoni A, et al. Halofuginone inhibits NF-kappaB and p38 MAPK in activated T cells. J Leukoc Biol. 2006;80:399–406.
85. Popov Y, Patsenker E, Bauer M, Niedobitek E, Schulze-Krebs A, Schuppan D. Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkappaB. J Biol Chem. 2006;281:15090–15098.
86. Pines M, Snyder D, Yarkoni S, Nagler A. Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biol Blood Marrow Transplant. 2003;9:417–425.
87. Saito S, Nishimura H, Phelps RG, et al. Induction of skin fibrosis in mice expressing a mutated fibrillin-1 gene. Mol Med. 2000;6:825–836.
88. Bona CA, Murai C, Casares S, et al. Structure of the mutant fibrillin-1 gene in the tight skin (TSK) mouse. DNA Res. 1997;4:267–271.
89. Siracusa LD, McGrath R, Ma Q, et al. A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation. Genome Res. 1996;6:300–313.
90. Lemaire R, Bayle J, Lafyatis R. Fibrillin in Marfan syndrome and tight skin mice provides new insights into transforming growth factor-beta regulation and systemic sclerosis. Curr Opin Rheumatol. 2006;18:582–587.
91. Anderson BE, Taylor PA, McNiff JM, et al. Effects of donor T cell trafficking and priming site on GVHD induction by naive and memory phenotype CD4 T cells. Blood. 2008, Blood -2007–2009;107953.
92. Anderson BE, Shlomchik W, Shlomchik M. Mechanisms of Chronic-Graft-Versus-Host Disease Induction and Pathogenesis in an MHC-Matched MiHA-Incompatible Murine Model. Blood. 2001;98 (Abstract 2727).
93. Matte-Martone C, Liu J, Jain D, McNiff J, Shlomchik WD. CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL. Blood. 2008;111: 3884–3892.
94. Claman HN. Mast cell depletion in murine chronic graft-versus- host disease. J Invest Dermatol. 1985;84:246–248.
95. Claman HN, Jaffee BD, Huff JC, Clark RA. Chronic graftversus- host disease as a model for scleroderma. II. Mast cell depletion with deposition of immunoglobulins in the skin and fibrosis. Cell Immunol. 1985;94:73–84.
96. Claman HN, Choi KL, Sujansky W, Vatter AE. Mast cell “disappearance” in chronic murine graft-vs-host disease (GVHD)- ultrastructural demonstration of “phantom mast cells”. J Immunol. 1986;137:2009–2013.
97. Levi-Schaffer F, Goldenhersh MA, Segal V, Nagler A. Nedocromil sodium ameliorates skin manifestations in a murine model of chronic graft-versus-host disease. Bone Marrow Transplant. 1997;19:823–828.
98. Korngold R, Sprent J. Features of T cells causing H-2-restricted lethal graft-vs.-host disease across minor histocompatibility barriers. J Exp Med. 1982;155:872–883.
99. Korngold R, Sprent J. T cell subsets and graft-versus-host disease. Transplantation. 1987;44:335–339.
100. Hattori H, Matsuzaki A, Suminoe A, et al. Polymorphisms of transforming growth factor-beta1 and transforming growth factor-beta1 type II receptor genes are associated with acute graft-versus-host disease in children with HLA-matched siblingbone marrow transplantation. Bone Marrow Transplant. 2002;30:665–671.
101. Middleton PG, Taylor PRA, Jackson G, Proctor SJ, Dickinson AM. Cytokine gene polymorphisms associating with severeacute graft-versus-host disease in HLA-identical sibling transplants. Blood. 1998;92:3943–3948.
102. Cavet J, Middleton PG, Segall M, Noreen H, Davies SM, Dickinson AM. Recipient tumor necrosis factor-alpha and interleukin 10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants. Blood. 1999;94:3941–3946.
103. Cavet J, Dickinson AM, Norden J, Taylor PR, Jackson GH, Middleton PG. Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood. 2001;98:1594–1600.
104. Ishikawa Y, Kashiwase K, Akaza T, et al. Polymorphisms in TNFA and TNFR2 affect outcome of unrelated bone marrow transplantation. Bone Marrow Transplant. 2002;29:569–575.
105. Berger M, Wettstein PJ, Korngold R. T cell subsets involved in ethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens. Transplantation. 1994;57:1095–1102.
106. Korngold R, Wettstein PJ. Immunodominance in the graft-vshost disease T cell response to minor histocompatibility antigens. J Immunol. 1990;145:4079–4088.
107. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graftversus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204–217.
108. Wingard JR, Piantadosi S, Vogelsang GB, et al. Predictors ofdeath from chronic graft-versus-host disease after bone marrow transplantation. Blood. 1989;74:1428–1435.
109. Fimiani M, De Aloe G, Cuccia A. Chronic graft versus host disease and skin. J Eur Acad Dermatol Venereol. 2003;17:512–517.
110. Skert C, Patriarca F, Sperotto A, et al. Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome. Haematologica. 2006;91:258–261.
111. Flowers ME, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood. 2002;100:415–419.
112. Mielcarek M, Martin PJ, Heimfeld S, Storb R, Torok-Storb B. CD34 cell dose and chronic graft-versus-host disease after human leukocyte antigen-matched sibling hematopoietic stem cell transplantation. Leuk Lymphoma. 2004;45:27–34.
113. Jones-Caballero M, Fernandez-Herrera J, Cordoba-Guijarro S, Dauden-Tello E, Garcia-Diez A. Sclerodermatous graft-versushost disease after donor leucocyte infusion. Br J Dermatol. 1998;139:889–892.
114. Ogawa Y, Kodama H, Kameyama K, et al. Donor fibroblast chimerism in the pathogenic fibrotic lesion of human chronic graft-versus-host disease. Invest Ophthalmol Vis Sci. 2005;46:4519–4527.
115. Wolff D, Reichenberger F, Steiner B, et al. Progressive interstitial fibrosis of the lung in sclerodermoid chronic graft-versushost disease. Bone Marrow Transplant. 2002;29:357–360.
116. Banning U, Krutmann J, Korholz D. The role of IL-4 and IL-12 in the regulation of collagen synthesis by fibroblasts. Immunol Invest. 2006;35:199–207.
117. Liem LM, Fibbe WE, van Houwelingen HC, Goulmy E. Serum transforming growth factor-beta1 levels in bone marrow transplant recipients correlate with blood cell counts and chronic graft-versus-host disease. Transplantation. 1999;67:59–65.
118. Keane MP, Gomperts BN, Weigt S, et al. IL-13 is pivotal in the fibro-obliterative process of bronchiolitis obliterans syndrome. J Immunol. 2007;178:511–519.
119. Gabrielli A, Svegliati S, Moroncini G, Luchetti M, Tonnini C, Avvedimento EV. Stimulatory autoantibodies to the PDGF receptor: a link to fibrosis in scleroderma and a pathway for novel therapeutic targets. Autoimmun Rev. 2007;7:121–126.
120. Svegliati S, Olivieri A, Campelli N, et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood. 2007;110:237–241.
121. Zhang C, Todorov I, Zhang Z, et al. Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood. 2006;107:2993–3001.
122. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3:541–547.
123. Williams LM, Rudensky AY. Maintenance of the Foxp3- dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol. 2007;8:277–284.
124. Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol. 2007;8:191–197.
125. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4(+)CD25(+) regulatory T cells. Nat Immunol. 2003;4:330–336.
126. Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4(+)CD25(+) T regulatory cells. Nat Immunol. 2003;4:337–342.
127. Parkman R. Clonal analysis of murine graft-vs-host disease. I. Phenotypic and functional analysis of T lymphocyte clones. J Immunol. 1986;136:3543–3548.
128. Agus DB, Surh CD, Sprent J. Reentry of T cells to the adult thymus is restricted to activated T cells. J Exp Med. 1991;173:1039–1046.
129. Hogquist KA, Baldwin TA, Jameson SC. Central tolerance:learning self-control in the thymus. Nat Rev Immunol.2005;5:772–782.
130. Fukushi N, Arase H, Wang B, et al. Thymus: a direct target tissue in graft-versus-host reaction after allogeneic bone marrow transplantation that results in abrogation of induction of selftolerance. Proc Natl Acad Sci U S A. 1990;87:6301–6305.
131. Hollander GA, Widmer B, Burakoff SJ. Loss of normal thymic repertoire selection and persistence of autoreactive T cells in graft vs host disease. J Immunol. 1994;152:1609–1617.
132. Bonasio R, Scimone ML, Schaerli P, Grabie N, Lichtman AH, von Andrian UH. Clonal deletion of thymocytes by circulating dendritic cells homing to the thymus. Nat Immunol. 2006;7:1092–1100.
133. Goldsobel AB, Haas A, Stiehm ER. Bone marrow transplantation in DiGeorge syndrome. J Pediatr. 1987;111:40–44.
134. Laufer TM, DeKoning J, Markowitz JS, Lo D, Glimcher LH. Unopposed positive selection and autoreactivity in mice expressing class II MHC only on thymic cortex. Nature. 1996;383:81–85.
135. Laufer TM, Fan L, Glimcher LH. Self-reactive T cells selected on thymic cortical epithelium are polyclonal and are pathogenic in vivo. J Immunol. 1999;162:5078–5084.
136. Capone M, Romagnoli P, Beermann F, MacDonald HR, van Meerwijk JP. Dissociation of thymic positive and negative selection in transgenic mice expressing major histocompatibility complex class I molecules exclusively on thymic cortical epithelial cells. Blood. 2001;97:1336–1342.
137. van Meerwijk JP, Marguerat S, Lees RK, Germain RN, Fowlkes BJ, MacDonald HR. Quantitative impact of thymic clonal deletion on the T cell repertoire. J Exp Med. 1997;185:377–383.
138. Marguerat S, MacDonald HR, Kraehenbuhl JP, van Meerwijk JP. Protection from radiation-induced colitis requires MHC class II antigen expression by cells of hemopoietic origin. J Immunol. 1999;163:4033–4040.
139. Teshima T, Reddy P, Liu C, Williams D, Cooke KR, Ferrara JL. Impaired thymic negative selection causes autoimmune graftversus- host disease. Blood. 2003;102:429–435.
140. Sakoda Y, Hashimoto D, Asakura S, et al. Donor-derived thymic- dependent T cells cause chronic graft-versus-host disease. Blood. 2007;109:1756–1764.
141. Zhang Y, Hexner E, Frank D, Emerson SG. CD4+ T cells generated de novo from donor hemopoietic stem cells mediate the evolution from acute to chronic graft-versus-host disease. J Immunol. 2007;179:3305–3314.
142. Tutschka PJ, Hess AD, Beschorner WE, Santos GW. Suppressor cells in transplantation tolerance. I. Suppressor cells in the mechanism of tolerance in radiation chimeras. Transplantation. 1981;32:203–209.
143. Glazier A, Tutschka PJ, Farmer ER, Santos GW. Graft-versus-host disease in cyclosporin A-treated rats after syngeneic and autologous bone marrow reconstitution. J Exp Med. 1983;158:1–8.
144. Sorokin R, Kimura H, Schroder K, Wilson DH, Wilson DB. Cyclosporine-induced autoimmunity. Conditions for expressing disease, requirement for intact thymus, and potency estimates of autoimmune lymphocytes in drug-treated rats. J Exp Med. 1986;164:1615–1625.
145. Beschorner WE, Hess AD, Shinn CA, Santos GW. Transfer of cyclosporine-associated syngeneic graft-versus-host disease by thymocytes. Resemblance to chronic graft-versus-host disease. Transplantation. 1988;45:209–215.
146. Fischer AC, Beschorner WE, Hess AD. Requirements for the induction and adoptive transfer of cyclosporine-induced syngeneic graft-versus-host disease. J Exp Med. 1989;169:1031–1041.
147. Hess AD, Fischer AC, Beschorner WE. Effector mechanisms in cyclosporine A-induced syngeneic graft-versus-host disease. Role of CD4+ and CD8+ T lymphocyte subsets. J Immunol. 1990;145:526–533.
148. Hess AD, Horwitz LR, Laulis MK, Fuchs E. Cyclosporineinduced syngeneic graft-vs-host disease: prevention of autoaggression by treatment with monoclonal antibodies to T lymphocyte cell surface determinants and to MHC class II antigens. Clin Immunol Immunopathol. 1993;69:341–350.
149. Fischer AC, Ruvolo PP, Burt R, et al. Characterization of the autoreactive T cell repertoire in cyclosporin-induced syngeneic graft-versus-host disease. A highly conserved repertoire mediates autoaggression. J Immunol. 1995;154:3713–3725.
150. Chen W, Thoburn C, Hess AD. Characterization of the pathogenic autoreactive T cells in cyclosporine-induced syngeneic graft-versus-host disease. J Immunol. 1998;161:7040–7046.
151. Hess AD, Thoburn C, Horwitz L. Promiscuous recognition of major histocompatibility complex class II determinants in cyclosporine-induced syngeneic graft-versus-host disease: specificity of cytolytic effector T cells. Transplantation. 1998;65:785–792.
152. Gold DP, Surh CD, Sellins KS, Schroder K, Sprent J, Wilson DB. Rat T cell responses to superantigens. II. Allelic differences in V beta 8.2 and V beta 8.5 beta chains determine responsiveness to staphylococcal enterotoxin B and mouse mammary tumor virus-encoded products. J Exp Med. 1994;179:63–69.
153. Surh CD, Gold DP, Wiley S, Wilson DB, Sprent J. Rat T cell response to superantigens. I. V beta-restricted clonal deletion of rat T cells differentiating in rat–>mouse chimeras. J Exp Med. 1994;179:57–62.
154. Hess AD, Bright EC, Thoburn C, Vogelsang GB, Jones RJ, Kennedy MJ. Specificity of effector T lymphocytes in autologous graft-versus-host disease: role of the major histocompatibility complex class II invariant chain peptide. Blood. 1997;89:2203–2209.
155. Yeager AM, Vogelsang GB, Jones RJ, et al. Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. Blood. 1992;79:3031–3035.
156. Jones RJ, Vogelsang GB, Hess AD, et al. Induction of graftversus- host disease after autologous bone marrow transplantation. Lancet. 1989;1:754–757.
157. Bolanos-Meade J, Garrett-Mayer E, Luznik L, et al. Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma. Biol Blood Marrow Transplant. 2007;13:1185–1191.
158. Gao EK, Lo D, Cheney R, Kanagawa O, Sprent J. Abnormal differentiation of thymocytes in mice treated with cyclosporine A. Nature. 1988;336:176–179.